Where is the ethical justification for charging rich-country prices for the new medicines that are relevant to poor countries when the profits subsidise research on diseases that have little relevance to them?
This suggests that protein engineering might be used to treat, and perhaps even to prevent, amyloid diseases, by allowing the manufacture of drugs that stabilise the relevant parts of the protein at risk.